BRAIN AGE®
HealthTech Technology

DiagnaMed Announces Canadian Launch of BRAIN AGE® Brain Health AI

TORONTO, April 23, 2024 — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, today announced that BRAIN AGE® Brain Health AI, a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score, is available to Canadian-based clinics focusing on health and wellness, sports and physical therapy, mental health, chiropractic care, or clinical and academic research for neurological and cognitive disorders.

Clinics in Canada can add BRAIN AGE® Brain Health AI by visiting BrainAge.ca.

Canada is at the forefront of supporting novel solutions for brain health. As announced on January 18, 2024, the Government of Ontario has committed $60 million dollars over a three-year period to support the Ontario Brain Institute (“OBI”) in its mission to accelerate solutions that improve brain health. An additional $5 million will be used to launch the Centre for Analytics, an initiative supporting the development of neuroanalytical skills and AI models while maximizing the value of the data collected across OBI’s research network. BRAIN AGE® Brain Health AI could complement these efforts in Canada to improve overall brain health.

BRAIN AGE® Brain Health AI is a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score. Based on research and development at Drexel University and the University of Miami, BRAIN AGE® Brain Health AI combines a brain age estimation and brain health assessment tool with the aim to ‘raise a red flag’ for potential brain health issues. BRAIN AGE® Brain Health AI can assess if a brain is aging more quickly or more slowly than is typical for healthy individuals. Brain age is estimated by collecting neural activity data of the brain with a low-cost and easy-to-use electroencephalogram headset and calculating the data with a proprietary machine-learning model. In addition, BRAIN AGE® Brain Health AI can assess if a person has a healthy brain or is in the early stage of cognitive decline. Brain health is scored by taking a clinically validated assessment for brain resilience, vulnerability and performance functions. Individuals can seek out personalized diagnostics and interventions, such as medication or lifestyle changes, that may help to decrease the development or progression of cognitive decline.

About DiagnaMed

DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is a healthcare technology company focused on brain health using AI. DiagnaMed is commercializing BRAIN AGE® Brain Health AI, a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score. Visit DiagnaMed.com.

For more information, please contact:

Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: [email protected]
Website: www.diagnamed.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “will”, “may”, “expect”, “could”, “can”, “estimate”, “anticipate”, “intend”, “believe”, “aims”, and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the three months ended December 31, 2023 (“MD&A”), dated February 29, 2024, which is available on the Company’s profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

Read more: Tome Biosciences to Present Data on Programmable Genomic Integration Technologies at ASGCT

Subscribe Now

    We send you the latest trends and best practice tips for online customer engagement:


    Receive Updates:

    Daily

    Weekly



    By completing and submitting this form, you understand and agree to HiTechNectar processing your acquired contact information as described in our privacy policy.

    We hate spams too, you can unsubscribe at any time.

      We send you the latest trends and best practice tips for online customer engagement:


      Receive Updates:

      Daily

      Weekly



      By completing and submitting this form, you understand and agree to HiTechNectar processing your acquired contact information as described in our privacy policy.

      We hate spams too, you can unsubscribe at any time.

      You have successfully subscribed to the newsletter

      There was an error while trying to send your request. Please try again.

      HitechNectar will use the information you provide on this form to be in touch with you and to provide updates and marketing.

        We send you the latest trends and best practice tips for online customer engagement:

        Receive Updates:   Daily    Weekly

        By completing and submitting this form, you understand and agree to HiTechNectar processing your acquired contact information as described in our privacy policy.

        We hate spams too, you can unsubscribe at any time.